News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Investor Alerts Year All Years 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Sep 20, 2022 Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Sep 1, 2022 Immunic, Inc. to Participate in Investor Conferences in September Aug 16, 2022 Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium Aug 4, 2022 Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update Aug 2, 2022 Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference Jul 28, 2022 Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update Jul 6, 2022 Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén Jun 28, 2022 Immunic to Participate in Industry and Scientific Conferences in July Jun 15, 2022 Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology Jun 8, 2022 Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June Show 5102550100 per page«123456789…13»
